BRCA1 and cervical squamous intraepithelial neoplasia: The TNT trial has compared the response between carboplatin and docetaxel, and biomarker subgroup analyses have revealed that among the Myriad-HRD status, BRCA mutation, BRCA mRNA level, BRCA1 promoter DNA methylation15, and structural chromosomal instability (CIN)30, only BRCA mutation and CIN predict a greater benefit from carboplatin over docetaxel in patients with metastatic TNBC, thus indicating a need for optimizing the HRD detection method.